Physician profile
Wesley Wright Davis
NPI 1376514422
$2,827.18
in general payments reported to CMS, 2019-2025
23 companies · $16.25 in 2025
The $16.25 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $536 · 2021: $719 · 2022: $577 · 2023: $302 · 2024: $91.49 · 2025: $16.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $405.60 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $359.31 | 2019-2022 | |
| Abbott Laboratories | $258.13 | 2019-2024 | Gallant |
| Bayer Healthcare Pharmaceuticals INC. | $257.66 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $216.70 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $199.98 | 2020-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $177.56 | 2019-2022 | |
| Abiomed | $164.24 | 2021-2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.00 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $94.30 | 2019-2023 | Eliquis |
| Amarin Pharma, INC. | $84.26 | 2020-2021 | |
| Philips North America LLC | $82.85 | 2023-2024 | (Ck4) Mcot |
| Arbor Pharmaceuticals, INC. | $56.19 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $49.39 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.51 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $47.44 | 2019 | |
| Irhythm Technologies, INC. | $32.74 | 2020-2022 | |
| Medtronic Vascular, INC. | $32.38 | 2019 | |
| Merck Sharp & Dohme LLC | $31.04 | 2022-2023 | Verquvo |
| Amgen INC. | $24.27 | 2023 | Repatha |
| Kiniksa Pharmaceuticals, Ltd. | $21.98 | 2023 | Arcalyst |
| Baxter Healthcare | $16.25 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.